LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Hologic Inc

Geschlossen

BrancheGesundheitswesen

64.32 2.11

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

62.96

Max

64.57

Schlüsselkennzahlen

By Trading Economics

Einkommen

-218M

-17M

Verkäufe

-17M

1B

KGV

Branchendurchschnitt

26.055

51.198

EPS

1.03

Gewinnspanne

-1.731

Angestellte

7,063

EBITDA

-359M

-7M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+5.36% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

28. Juli 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-1.1B

14B

Vorheriger Eröffnungskurs

62.21

Vorheriger Schlusskurs

64.32

Nachrichtenstimmung

By Acuity

24%

76%

56 / 380 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Hologic Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

27. Mai 2025, 18:46 UTC

Wichtige Markttreiber
Akquisitionen, Fusionen, Übernahmen

Hologic Shares Up Following Report of Buyout Offer From TPG, Blackstone

27. Mai 2025, 20:07 UTC

Akquisitionen, Fusionen, Übernahmen

Hologic Stock Is Surging. Why Shares of the MedTech Company Are Up 14%. -- Barrons.com

27. Mai 2025, 19:06 UTC

Akquisitionen, Fusionen, Übernahmen

Hologic Stock Is Surging. Why Shares of the MedTech Company Are Up 14%. -- Barrons.com

27. Mai 2025, 18:26 UTC

Akquisitionen, Fusionen, Übernahmen

Hologic Stock Is Surging. Why Shares of the MedTech Company Are Up 19%. -- Barrons.com

Peer-Vergleich

Kursveränderung

Hologic Inc Prognose

Kursziel

By TipRanks

5.36% Vorteil

12-Monats-Prognose

Durchschnitt 66.45 USD  5.36%

Hoch 71 USD

Tief 60 USD

Basierend auf 14 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Hologic Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

14 ratings

5

Buy

9

Halten

0

Sell

Technischer Score

By Trading Central

52.69 / 58.605Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Weak Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

56 / 380 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Hologic Inc

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.